Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.

Link to article at PubMed

Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.

Am J Cardiol. 2020 May 16;:

Authors: Aggarwal G, Henry BM, Aggarwal S, Bangalore S

Abstract
Coronavirus disease 2019 (COVID-19) has become a global pandemic. It is still uncontrolled in most countries and no therapies are currently available. Various drugs are under investigation for its treatment. The disease is known to have worse outcomes in patients who have underlying cardiovascular disease. Chloroquine/hydroxychloroquine, azithromycin, remdesivir and lopinavir/ritonavir are currently being studied in trials and show some promise. Conduction disorders, heart failure and mortality have been reported with the use of these drugs. It is important to have a knowledge of potential cardiotoxic effects of these drugs before using them for COVID-19 patients for better allocation of healthcare resources and improvement in clinical outcomes.

PMID: 32425199 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published.